Successful treatment of relapsed Waldenström’s macroglobulinemia with proteasome inhibitors (bortezomib and subsequently ixazomib) in combination with rituximab and dexamethasone. A case report and review of the of proteasome inhibitors in Waldenström’s macroglobulinemia

Česká verzia

Authors: Z. Adam ¹; M. Krejčí ¹; L. Pour ¹; B. Weinbergerová ¹; V. Sandecká ¹; M. Štork ¹; I. Boichuk ¹; Z. Řehák ²; M. Keřkovský ³; R. Koukalová ²; L. Zdražilová-Dubská ^4,5; B. Čechová ³; Z. Král ¹
Authors place of work: Interní hematologická a onkologická klinika LF MU a FN Brno ¹; Oddělení nukleární medicíny, MOU Brno ²; Klinika radiologie a nukleární medicíny LF MU a FN Brno ³; Ústav laboratorní medicíny LF MU a FN Brno ⁴; Katedra laboratorních metod a CREATIC, LF MU Brno ⁵
Published in the journal: Klin Onkol 2024; 39(6): 451-462
Category: Case Reports
doi: https://doi.org/10.48095/ccko2024451

Summary

Background: Waldenström’s macroglobulinemia (WM) is a very rare disease with an incidence 10times lower than that of multiple myeloma. The incidence of WM is also significantly lower than that of the other CD20+ low-grade lymphomas. The rarity of WM is the reason why registration studies of new drugs used for multiple myeloma or the more common CD20+low-grade lymphomas do not cover WM. Data on the efficacy of proteasome inhibitors in WM can be drawn from case descriptions, small series of patients and a few phase II clinical trials. The aim of this case report and review is to inform about our experience with the treatment of WM with bortezomib and then ixazomib and to present an overview of publications on proteasome inhibitors in WM. Case: We describe a patient who, after 8 years of asymptomatic course of WM, had the first fulminant progression with severe pancytopenia at the age of 74 years. For the first-line treatment, he was treated with dexamethasone and rituximab, and after alleviation of pancytopenia, with bendamustine. Monoclonal immunoglobulin IgM (M-IgM) dropped from 40 g/L to the level as low as 6.9 g/L, which meant partial remission (PR) accompanied with normal blood count values. After 29 months of PR, the patient experienced a fulminant relapse of WM, accompanied by severe pancytopenia. Rituximab and dexamethasone were the backbone of treatment with addition of bortezomib for its significantly lower myelosuppression compared to alkylating agents. Treatment with the triple combination of bortezomib, rituximab, and dexamethasone was effective, however, after five cycles, bortezomib had to be discontinued for severe neurotoxicity. The sixth cycle contained rituximab and dexamethasone, and from the seventh cycle, ixazomib was started. The patient underwent seven cycles (months) of treatment consisting of ixazomib, rituximab and dexamethasone (14 cycles of treatment in total). Results: M-IgM decreased from 30 g/L at the beginning of the treatment to 4.0 g/L at the end of treatment and further decreased to a value of 2.8 g/L at the eighth month after the end of the treatment. A deeper decrease in M-IgM than after first-line treatment was achieved and the patient now meets the criteria for a very good partial remission. Conclusion: According to the described experience and according to the review of publications evaluating proteasome inhibitors in WM, the combination of ixazomib with rituximab and dexamethasone excels with very good tolerance and high efficacy, approaching the efficacy of the combination of rituximab with bendamustine. This combination has its place particularly in patients with WM and cytopenia.

Keywords:

bortezomib – Waldenström’s macroglobulinemia – ixazomib

Zdroje

1. Flodr P, Adam Z, Navrátilová M et al. Poškození způsobená depozity monoklonálního imunoglobulinu typu IgM a lehkými řetězci u Waldenströmovy makroglobulinémie – popis případu a přehled literatury. Trans Hematol Dnes 2024; 30 (2): 99–111. doi: 10.48095/cctahd2024prolekare.cz8.

2. Adam Z, Zdražilová Dubská L et al. Kryoglobulinemie z úhlu pohledu jednotlivých medicínských odborností. [In press]. Transf Hematol Dnes 2024.

3. Baďurová K, Gregorová M, Vlachová M et al. Waldenströmova makroglobulinemie. Klin Onkol 2021; 34 (6): 428–433. doi: 10.48095/ccko2021428.

4. Kaščák M, Chyra Z, Growková K. Standardizace testování somatických mutací v genech MYD88A CXCR4 z kostní dřeně a periferní krve u pacientů s Waldenströmovou makroglobulinemií v České republice. Trans Hematol Dnes 2018; 24 (Suppl 2): 52–53.

5. Wang H, Chen Y, Li F et al. Temporal and geographic variations of Waldenström macroglobulinemia incidence: a large population-based study. Cancer 2012; 118 (15): 3793–3800. doi: 10.1002/cncr.26627.

6. McMaster ML. The epidemiology of Waldenström macroglobulinemia. Semin Hematol 2023; 60 (2): 65–72. doi: 10.1053/j.seminhematol.2023.03.008.

7. Castillo JJ, Olszewski AJ, Kanan S et al. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol 2015; 169 (1): 81–89. doi: 10.1111/bjh.13264.

8. Hájek R. Diagnostika a léčba Waldenströmovy makroglobulinémie: doporučení vypracovaná Českou myelomovou skupinou (CMG), myelomovou sekcí České hematologické společnosti ČLS JEP a Kooperativní lymfomovou skupinou lymfomovou sekcí České hematologické společnosti ČLS JEP. Trans Hematol Dnes 2022; 28 (Suppl 1): 42–74.

9. Andrade-Campos M, Murillo-Flórez I, García-Sanz R et al Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression. Clin Chem Lab Med 2017; 55 (10): 1598–1604. doi: 10.1515/cclm-2016-0748.

10. Kleinstern G, Larson DR, Allmer C et al. Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. Blood Cancer J 2022; 12 (4): 67. doi: 10.1038/s41408-022-00659-9.

11. Advani P, Paulus A, Ailawadhi S. Updates in prognostication and treatment of Waldenström’s macroglobulinemia. Hematol Oncol Stem Cell Ther 2019; 12 (4): 179–188. doi: 10.1016/j.hemonc.2019.05.002.

12. Dogliotti I, Jiménez C, Varettoni M et al. Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia. Leukemia 2023; 37 (2): 388–395. doi: 10.1038/s41375-022-01762-3.

13. Kastritis E, Morel P, Duhamel A et al. A revised international prognostic scoresystem for Waldenström’s macroglobulinemia. Leukemia 2019; 33 (11): 2654–2661. doi: 10.1038/s41375-019-0431-y.

14. Tadmor T, Braester A, Najib D et al. A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain. Eur J Haematol 2019; 103 (4): 335–341. doi: 10.1111/ejh.13288.

15. Bockorny B, Atienza JA, Dasanu CA. Autoimmune manifestations in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 2014; 14 (6): 456–459. doi: 10.1016/j.clml.2014.04.009.

16. Vaxman I, Shepshelovich D, Hayman L et al. Agranulocytosis associated with Waldenström macroglobulinemia. Acta Haematol 2018; 140 (1): 42–45. doi: 10.1159/000489482.

17. van Gelder M, van Marion A, Goossens V et al. Resolution of Waldenström’s macroglubulinemia related isolated neutropenia by immunochemotherapy. Am J Hematol 2011; 86 (4): 380–382. doi: 10.1002/ajh.21990.

18. Velier M, Priet S, Appay R et al. Severe and irreversible pancytopenia associated with SARS-CoV-2 bone marrow infection in a patient with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 2021; 21 (6): e503–e505. doi: 10.1016/j.clml.2021.01.005.

19. Diez-Feijóo R, Rodríguez-Sevilla JJ, Fernández-Rodríguez C et al. Case report: high doses of intravenous immunoglobulins as a successful treatment for late onset immune agranulocytosis after rituximab plus bendamustine. Front Immunol 2022; 12: 798251. doi: 10.3389/fimmu.2021.798251.

20. Getta B, Ponniah G, Ling S. Intravenous immunoglobulin induces short-term reversal of drug-induced autoimmune neutropenia. Transfus Med 2015; 25 (5): 347–348. doi: 10.1111/tme.12228.

21. Kimby E, Treon SP, Anagnostopoulos A et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom’s Macroglobulinemia. Clin Lymphoma Myeloma 2006; 6 (5): 380–383. doi: 10.3816/CLM.2006.n.013.

22. Treon SP, Tedeschi A, San-Miguel J et al. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom’s macroglobulinemia on diagnostic and response criteria. Semin Hematol 2023; 60 (2): 97–106. doi: 10.1053/j.seminhematol.2023.03.009.

23. Chen CI, Kouroukis CT, White D et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25 (12): 1570–1575. doi: 10.1200/JCO.2006.07. 8659.

24. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC et al. Treatment of relapsed or refractory Waldenström’s macroglobulinemia with bortezomib. Haematologica 2005; 90 (12): 1655–1658.

25. Treon S, Hunter Z, Matous J et al. Phase II study of bortezomib in Waldenstrom’s macroglobulinemia: results of WMCTG trial 03-248. Blood 2005; 106 (11): 147A. doi: 10.1182/blood.V106.11.490.490.

26. Ghobrial IM, Xie W, Padmanabhan S et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström macroglobulinemia. Am J Hematol 2010; 85 (9): 670–674. doi: 10.1002/ajh.21788.

26. Zhang YP, Yang X, Lin ZH et al. Low-dose bortezomib and dexamethasone as primary therapy in elderly patients with Waldenstrőm macroglobulinemia. Eur J Haematol 2017; 99 (6): 489–494. doi: 10.1111/ejh.12935.

27. Treon SP, Ioakimidis L, Soumerai JD et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27 (23): 3830–3835. doi: 10.1200/JCO.2008.20.4677.

28. Dimopoulos MA, García-Sanz R, Gavriatopoulou M et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood 2013; 122 (19): 3276–3282. doi: 10.1182/blood-2013-05-503862.

29. Gavriatopoulou M, García-Sanz R, Kastritis E et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood 2017; 129 (4): 456–459. doi: 10.1182/blood-2016-09-742411.

30. Auer RL, Owen RG, D’Sa S et al. Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for initial therapy of Waldenström’s macroglobulinemia: a randomised phase II study. Blood 2016; 128 (22): 618. doi: 10.1182/blood.V128.22.618.618.

31. Leblebjian H, Noonan K, Paba-Prada C et al. Cyclophosphamide, bortezomib, and dexamethasone combination in Waldenstrom macroglobulinemia. Am J Hematol 2015; 90 (6): E122–E123. doi: 10.1002/ajh.23985.

32. Castillo JJ, Gustine JN, Meid K et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol 2018; 181 (1): 77–85. doi: 10.1111/bjh.15148.

33. Abeykoon JP, Zanwar S, Ansell SM et al. Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. Am J Hematol 2021; 96 (8): 945–953. doi: 10.1002/ajh.26210.

34. Buske C, Dimopoulos MA, Grunenberg A et al. Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenström’s macroglobulinemia: a prospectively randomized trial of the European Consortium for Waldenström’s Macroglobulinemia. J Clin Oncol 2023; 41 (14): 2607–2616. doi: 10.1200/JCO.22.01805.

35. Rossi G, Gramegna D, Paoloni F et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood 2018; 132 (5): 547–550. doi: 10.1182/blood-2018-03-835413.

36. Kong D, Li Y, Fu C et al. Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia. Leuk Lymphoma 2022; 63 (2): 491–494. doi: 10.1080/10428194.2021.1992766.

37. Ojeda-Uribe M, Rimelen V, Marzullo C. Good profile of efficacy/tolerance of bortezomib or idelalisib in Waldenström macroglobulinemia associated with acquired von Willebrand syndrome. J Blood Med 2020; 11: 67–72. doi: 10.2147/JBM.S233059.

38. Baird SM, Kenealy MK, Hoy R. Complete remission of Waldenström’s associated generalized crystal-storing histiocytosis of IgM lambda subtype with bortezomib-based combination chemotherapy. Leuk Lymphoma 2015; 56 (11): 3233–3235. doi: 10.3109/10428194.2015. 1036261.

39. Sklavenitis-Pistofidis R, Capelletti M, Liu CJ et al. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood 2018; 132 (24): 2608–2612. doi: 10.1182/blood-2018-07-863241.

40. Khwaja J, Uppal E, Baker R et al. Bortezomib-based therapy is effective and well tolerated in frontline and multiply pre-treated Waldenström macroglobulinaemia including BTKi failures: a real-world analysis. Eur J Haematol 2022; 3 (4): 1330–1334. doi: 10.1002/jha2.597.

41. Sacco A, Aujay M, Morgan B et al. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom’s macroglobulinemia. Clin Cancer Res 2011; 17 (7): 1753–1764. doi: 10.1158/1078-0432.CCR-10-2130.

42. Morra E. Carfilzomib: a new opportunity for WM patients. Blood 2014; 124 (4): 468–469. doi: 10.1182/blood-2014-06-578625.

43. Treon SP, Tripsas CK, Meid K et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström’s macroglobulinemia. Blood 2014; 124 (4): 503–510. doi: 10.1182/blood-2014-03-566273.

44. Alfaraj WA, Cachia D, Tummala S et al. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström’s macroglobulinemia. Ann Hematol 2016; 95 (2): 347–348. doi: 10.1007/s00277-015-2516-7.

45. Chaudhry M, Steiner R, Claussen C et al. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström’s macroglobulinemia. Leuk Lymphoma 2019; 60 (4): 964–970. doi: 10.1080/10428194.2018.1508668.

46. Vesole DH, Richter J, Biran N et al. Carfilzomib as salvage therapy in Waldenström macroglobulinemia: a case series. Leuk Lymphoma 2018; 59 (1): 259–261. doi: 10.1080/10428194.2017.1321749.

47. Krhovská P, Minařík J. Ixazomib – první perorální inhibitor proteazomu. Remedia 2017; 27 (5): 461–465.

48. Plonková H, Jelínek T, Szeligová L et al. První perorální inhibitor proteazomu v léčbě relabujícího/refrakterního mnohočetného myelomu. Trans Hematol Dnes 2017; 23 (4): 199–209.

49. Maisnar V. Inhibitory proteasomu v léčbě mnohočetného myelomu. Farmakoterapie 2021; 17 (2): 183–193.

50. Minařik J, Radocha J, Jungova A et al. Ixazomib, lenalidomide and dexamethasone in relapsed and refractory multiple myeloma in routine clinical practice: extended follow-up analysis and the results of subsequent therapy. Cancers 2022; 14 (20): 5165. doi: 10.3390/cancers14205165.

51. Minařík J, Pika T, Radocha J et al. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer 2021; 21 (1): 73. doi: 10.1186/s12885-020-07732-1.

52. Castillo JJ, Meid K, Gustine JN et al. Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in Waldenström macroglobulinemia. Clin Cancer Res 2018; 24 (14): 3247–3252. doi: 10.1158/1078-0432.CCR-18-0152.

53. Castillo JJ, Meid K, Flynn CA et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. Blood Adv 2020; 4 (16): 3952–3959. doi: 10.1182/bloodadvances.2020001963.

54. Kersten MJ, Amaador K, Minnema MC et al. Combining ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory Waldenström’s macroglobulinemia: final analysis of the phase I/II HOVON124/ECWM-R2 study. J Clin Oncol 2022; 40 (1): 40–51. doi: 0.1200/JCO.21.00105.

55. Solia E, Dimopoulos MA, Kastritis E. Proteasome inhibitor-based regimens in the frontline management of Waldenström macroglobulinemia. Hematol Oncol Clin North Am 2023; 37 (4): 689–705. doi: 10.1016/j.hoc.2023.04.004.

56. Parrondo RD, Dutta N, LaPlant BR et al. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia. Br J Haematol 2024; 204 (5): 1825–1829. doi: 10.1111/bjh.19320.

57. Cohen C, Royer B, Javaugue V et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 2015; 88 (5): 1135–1143. doi: 10.1038/ki.2015.201.

58. Baird SM, Kenealy MK, Hoy R. Complete remission of Waldenström’s associated generalized crystal-storing histiocytosis of IgM lambda subtype with bortezomib-based combination chemotherapy. Leuk Lymphoma 2015; 56 (11): 3233–3235. doi: 10.3109/10428194.2015.1036261.

59. Wu X, Zhang L, Feng J et al. Bortezomib-based chemotherapy can improve renal and tubular functions in patients with light chain-associated Fanconi syndrome. Ann Hematol 2019; 98 (5): 1095–1100. doi: 10.1007/s00277-018-3572-6.

60. Merlini G, Sarosiek S, Benevolo G et al. Report of consensus panel 6 from the 11 th International Workshop on Waldenström’s macroglobulinemia on management of Waldenström’s macroglobulinemia related amyloidosis. Semin Hematol 2023; 60 (2): 113–117. doi: 10.1053/j.seminhematol.2023.03.002.

61. Banwait R, O’Regan K, Campigotto F et al. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. American J Hematology 2011; 86 (7): 567–572. doi: 10.1002/ajh.22044.

62. Pan B, Zhu X, Xie Q. The performance and applied value of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Nucl Med Mol Imaging 2023; 13 (5): 217–224.

63. Zhou M, Chen Y, Liu J et al. A predicting model of bone marrow malignant infiltration in 18F-FDG PET/CT images with increased diffuse bone marrow FDG uptake. J Cancer 2018; 9 (10): 1737–1744. doi: 10.7150/jca.24836.

64. Cao X, Ye Q, Orlowski RZ et al. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol 2015; 8: 74. doi: 10.1186/s13045-015-0172-y.

65. Pan Q, Cao X, Luo Y et al. Baseline 18 F-FDG PET/CT may portend the prognosis of patients with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma after first-line treatment. Clin Nucl Med 2022; 47 (11): 954–960. doi: 10.1097/RLU.0000000000004362.

66. Durot E, Tomowiak C, Michallet AS et al. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO). Br J Haematol 2017; 179 (3): 439–448. doi: 10.1111/bjh.14881.

67. Bhatti K, Nazir A, Ostergaard S et al. Bone involvement as a primary rare manifestation of Waldenstrom macroglobulinemia: a case report and prevalence in a nationwide population-based cohort study. J Hematol 2022; 11 (6): 233–239. doi: 10.14740/jh1073.

68. Pan Q, Luo Y, Cao X et al. Bing-Neel syndrome and coexisting pituitary macroadenoma in a patient with Waldenström macroglobulinemia revealed by 18F-FDG and 68Ga-pentixafor PET/CT. Diagnostics 2023; 13 (7): 1334. doi: 10.3390/diagnostics13071334.

69. Pan Q, Cao X, Luo Y et al. Chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma: comparison to 18F-FDG PET/CT. Clin Nucl Med 2021; 46 (9): 732–737. doi: 10.1097/RLU.000 0000000003760.

70. Krejci M, Pour L, Adam Z et al. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. Ann Hematol 2021; 100 (10): 2541–2546. doi: 10.1007/s00277-021-04594-w.

71. Terpos E, Branagan AR, García-Sanz R et al. Report of consensus panel 5 from the 11th international workshop on Waldenstrom’s macroglobulinemia on COVID-19 prophylaxis and management. Semin Hematol 2023; 60 (2): 107–112. doi: 10.1053/j.seminhematol.2023.03.004.

72. Weinbergerova B, Mayer J, Kabut T et al. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients. Hematol Oncol 2021; 39 (5): 715–720. doi: 10.1002/hon.2908.

73. Weinbergerova B, Mayer J, Hrabovsky S et al. COVID-19’s natural course among ambulatory monitored outpatients. Sci Rep 2021; 11 (1): 10124. doi: 10.1038/s41598-021-89545-1.

74. Adam Z, Pour L, Krejčí M et al. Léčebná kombinace obinutuzumabu, bendamustinu a dexametazonu dosáhla u pěti pacientů s Waldenströmovou makroglobulinémií hlubší léčebné odpovědí než předchozí linie léčby. [In press]. Klin Onkol 2024.

75. Adam Z, Pour, L, Zeman D et al. Waldenström’s macroglobulinemia – clinical symptoms and review of therapy yesterday, today and tomorrow. Klin Onkol 2023; 36 (3): 177–191. doi: 10.48095/ccko2023177.

76. Dimopoulos MA, Opat S, D’Sa S et al. Zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia: final analysis from the randomized phase III ASPEN study. J Clin Oncol 2023; 41 (33): 5099–5106. doi: 10.1200/JCO.22.02830.